bluewindmedical

BlueWind Medical is the maker of Revi®, a transformative medical device for the treatment of urge urinary incontinence.

[bluewindmedical @bluewindinc]

Our publication, “Two-year efficacy and safety outcomes of the pivotal OASIS Study using the Revi® System for treatment of urgency urinary incontinence,” is now available in the @JUrology!

Learn more in our press release: https://t.co/qER8KYUosl

#Urology #OAB

[bluewindmedical @bluewindinc]

Despite its prevalence, many people living with urinary incontinence delay seeking care, often assuming bladder leaks are simply a normal part of aging.

In reality, there are many effective ways to manage and improve symptoms.

Learn more: https://t.co/QQ0CEmR4h4

#Urology #Urogyn #BladderHealth

[bluewindmedical @bluewindinc]

We're heading to #IFRUE2026 in Denver!

#IFRUE brings together leaders across urology to discuss emerging technologies, innovative treatment approaches, and the future of patient care.

Learn more: https://t.co/cDsvyp8PAM

@IFRUEUrol
#Urology #Urogyn

[bluewindmedical @bluewindinc]

We're proud to share that the FDA has granted 510(k) clearance for the Revi® System, including an extension of the implant component's indicated lifetime to 15 years. As part of this milestone, the implant component will be rebranded as Revi® Extend.

Learn more: https://t.co/HT5Hi8oY63

#Urology #Urogyn #Incontinence #Neuromodulation #UUI

[bluewindmedical @bluewindinc]

🎉 Congrats to Dr. Eric Espinosa of Ohio Valley Surgical Hospital on completing 100 #Revi implant procedures!

This milestone is a testament to Dr. Espinosa and his team's dedication to caring for people living with urgency urinary incontinence and expanding their treatment options.

#UUI #Urology

[bluewindmedical @bluewindinc]

For people living with #UUI, chronic symptoms often impact daily routines and active lifestyles.

Patients treated with Revi® experienced sustained improvements in sleep, social engagement, coping, and overall well-being.

Learn more: https://t.co/QQ0CEmR4h4

#NationalWellnessMonth

[bluewindmedical @bluewindinc]

Designed with patients and providers in mind, #Revi combines a miniature implant with wearable-powered technology for a personalized treatment experience.

At 36 months:
✓ 95% patient satisfaction
✓ 79% achieved ≥50% reduction in #UUI episodes

Learn more: https://t.co/ThsUQBucJf

#ChooseRevi #Urology #Urogyn

[bluewindmedical @bluewindinc]

Understanding the factors that may contribute to urinary incontinence symptoms is an important step toward earlier diagnosis, informed treatment decisions, and improved quality of life.

Learn more about Revi® and Urgency Urinary Incontinence management:

https://t.co/jH8RxzYjl8

#UUI #BladderHealth #Urology #Urogyn

[bluewindmedical @bluewindinc]

Summer is meant for making memories, not planning around #UUI symptoms.

95% of patients reported therapeutic satisfaction at 36 months with #Revi, helping them get back to the activities they love.

Learn more: https://t.co/lbcSRKdl6h

#ChooseRevi #BladderHealth #Urology

[bluewindmedical @bluewindinc]

New data support Revi® as both a standalone therapy and a complementary treatment option used in combination with OAB medication, helping support a more personalized, shared decision-making approach to care.

Learn more: https://t.co/DPvWrgJVdV

#Urology #Urogyn

[bluewindmedical @bluewindinc]

Three-year OASIS data reinforce #Revi’s durability, safety, and 95% patient satisfaction.

Hear insights from Dr. Roger Dmochowski: https://t.co/6AA9cDDCUE

#ChooseRevi #Urology #Urogyn #Neuromodulation

[bluewindmedical @bluewindinc]

Managing #UUI can be limited by prescription side effects, treatment adherence, and ongoing therapy burden.

Revi® offers a different approach.

79% of patients maintained therapeutic benefit at 36 months, without frequent in-office visits.

Learn more: https://t.co/PCr2OqH2fV

#ChooseRevi #Neuromodulation

[bluewindmedical @bluewindinc]

#ICYMI: New data presented at #IUGA2026 explored the impact of #OAB medication use in patients treated with Revi® for urgency urinary incontinence (#UUI).

Findings support Revi as both a standalone therapy and a complementary option alongside medication for durable symptom relief.

Learn more: https://t.co/zDK71vNvIQ

#Urology #Urogyn #Neuromodulation

[bluewindmedical @bluewindinc]

Did you know? 💡

Urinary Incontinence impacts an estimated 100M people in the U.S. alone.

This #WorldContinenceWeek, we’re focused on breaking the silence, raising awareness, and encouraging open conversations about #BladderHealth.

Explore resources from @WFIP_Official: https://t.co/ed9ofATySG

#WCW2026 #Urology #Urogyn

[bluewindmedical @bluewindinc]

We’re live at #IUGA2026!

Join us tomorrow as we share new insights from the OASIS clinical trial, exploring the use of medication in combination with #Revi for patients living with #UUI.

Learn more: https://t.co/byo7eTGVuS

@iugaoffice

#IUGA #Urology #Urogyn

[bluewindmedical @bluewindinc]

#ICYMI: We recently announced the close of $47.8 million in financing to accelerate the commercialization of Revi® and expand access to Implantable Tibial Neuromodulation (ITNM) for patients living with urgency urinary incontinence (#UUI).

Read more in @MassDevice: https://t.co/uWb4tSSZb7

#Urology #Urogyn #Revi

[bluewindmedical @bluewindinc]

#ICYMI: Two-year quality-of-life (QoL) outcomes with Revi for urgency urinary incontinence (UUI) were published in The International Urogynecology Journal.

Learn more about the clinically meaningful and sustained improvements in QoL through two years: https://t.co/KZykrjYqrO

#Urology #Urogynecology #Neuromodulation

[bluewindmedical @bluewindinc]

With a simple outpatient procedure, #Revi provides a personalized solution for #UUI, resulting in 95% patient satisfaction.

Today, Renee is no longer held back by UUI symptoms, and wants others to know there’s hope.

Learn more: https://t.co/6fMkxIeV2f

#Urology #Urogyn #ChooseRevi

[bluewindmedical @bluewindinc]

Living with Urgency Urinary Incontinence (#UUI) often means disrupted sleep – taking a real toll on daily life.

Patients treated with #Revi experienced reduced nocturia episodes, from 1.3 to 0.9 per day – sustained over 3 years.

Read more in The Journal of Urology: https://t.co/6zCLI4caK7

@AmerUrological

[bluewindmedical @bluewindinc]

And that’s a wrap on #AUA2026!

We’re always grateful for the opportunity to connect with leading clinicians and researchers, aiming to advance #UUI care.

Missed us on-site? Learn more here: https://t.co/Uc3XCuDORe

@AmerUrological

#AUA #Urology #Urogyn

[bluewindmedical @bluewindinc]

Heading to #AUA2026 this week?

Don’t forget to stop by Booth #4127 to learn more about #Revi – the most clinically validated implantable tibial neuromodulation therapy for Urgency Urinary Incontinence (#UUI).

See you there!

https://t.co/vJKx4AKKAL

@AmerUrological

#AUA #Urology #Urogyn